Litigation & Appeals

Click here to view our Litigation & Appeals professionals

Our attorneys have an exceptional range of litigation experience and technical knowledge.

We try cases and we win. Our attorneys represent clients aggressively, effectively, and efficiently in all types of intellectual property litigation before all forums, including the federal courts, the International Trade Commission, the U.S. Patent and Trademark Office, and in private mediation. Our clients include a wide range of companies, from small start-ups to Fortune 100 companies. We represent both plaintiff and defense positions in litigation.

Our attorneys are experienced with litigating disputes over patent, trademark and copyright infringement, trade secret misappropriation, and unfair competition. We represent clients in interference proceedings and trademark opposition and cancellation proceedings. Our technical skills extend to numerous technology areas, including biotechnology, business methods, chemical, computing, electrical, mechanical and materials, pharmaceuticals and diagnostics, and telecommunications.

At MBHB, our broad litigation experience and technical knowledge are particularly valuable to clients in protecting and enforcing their rights through a variety of infringement litigation procedures, including temporary restraining orders, preliminary injunctions, Markman hearings, bench and jury trials, and appeals. Even in the heat of litigation, we keep our focus on our clients' business goals. We always understand what is truly important to our clients.

P: 312.913.2104
F: 312.913.0002
P: 312.935.2369
F: 312.913.0002
P: 312.913.2140
F: 312.913.0002
P: 312.913.2130
F: 312.913.0002
P: 312.913.2144
F: 312.913.0002
P: 312.913.3330
F: 312.913.0002
P: 312.913.2131
F: 312.913.0002
P: 312.913.3345
F: 312.913.0002
P: 312.913.3341
F: 312.913.0002
P: 312.913.3317
F: 312.913.0002
P: 312.913.2109
F: 312.913.0002
P: 312.913.2121
F: 312.913.0002
P: 360.379.6514
F: 312.913.2557
P: 312.913.2143
F: 312.913.0002
P: 312.913.3315
F: 312.913.0002
P: 312.913.2139
F: 312.913.0002
P: 312.913.3333
F: 312.913.0002
P: 312.913.2107
F: 312.913.0002
P: 312.913.3366
F: 312.913.0002
P: 312.913.3395
F: 312.913.0002
P: 312.913.2116
F: 312.913.0002
P: 312.913.2106
F: 312.913.0002
P: 312.913.3331
F: 312.913.0002
P: 312.913.2122
F: 312.913.0002
P: 312.913.2137
F: 312.913.0002
P: 312.935.2372
F: 312.913.0002
P: 312.913.3377
F: 312.913.0002
P: 312.913.3304
F: 312.913.0002
P: 312.913.2125
F: 312.913.0002
P: 312.913.3311
F: 312.913.0002
P: 312.913.2112
F: 312.913.0002
P: 312.913.3372
F: 312.913.0002
P: 312.913.2129
F: 312.913.0002
P: 312.913.2101
F: 312.913.0002
P: 312.935.2359
F: 312.913.0002
P: 312.913.3344
F: 312.913.0002
P: 312.913.3350
F: 312.913.0002
P: 312.913.3302
F: 312.913.0002
P: 312.935.2370
F: 312.913.0002
P: 312.913.2145
F: 312.913.0002
P: 312.913.3354
F: 312.913.0002
P: 312.913.3396
F: 312.913.0002
P: 312.913.3335
F: 312.913.0002
P: 312.913.3349
F: 312.913.0002
P: 312.913.2118
F: 312.913.0002
P: 312.935.2366
F: 312.913.0002
P: 312.913.3303
F: 312.913.0002
P: 312.913.3376
F: 312.913.0002
P: 312.913.3347
F: 312.913.0002
P: 312.913.2133
F: 312.913.0002
P: 312.913.3351
F: 312.913.0002
P: 312.913.3356
F: 312.913.0002
P: 312.913.2119
F: 312.913.0002
P: 312.913.3336
F: 312.913.0002
P: 312.913.0001
F: 312.913.0002
P: 312.913.3348
F: 312.913.0002
P: 312.913.3329
F: 312.913.0002
P: 312.913.3300
F: 312.913.0002
P: 312.935.2379
F: 312.913.0002
P: 312.913.2128
F: 312.913.0002
P: 312.913.3368
F: 312.913.0002
P: 312.913.2138
F: 312.913.0002
P: 312.913.3301
F: 312.913.0002
Partner
P: 312.913.3390
F: 312.913.0002

Upcoming Events

April 4, 2017
MBHB Partner Marcus Thymian Is a Featured Presenter
April 18, 2017
MBHB Partner Joshua Rich Is the Featured Presenter
May 9-11, 2017
MBHB Partners Dr. Kevin Noonan and Dr. Donald Zuhn Are Featured Presenters

Past Event

March 14, 2017
MBHB Partners Dr. Andrew Williams and James Lovsin Are the Featured Presenters
March 7, 2017
MBHB Partner Dr. Emily Miao is a Featured Presenter
March 7, 2017
MBHB Partner Dr. Andrew Williams Is Featured Presenter
February 22, 2017
January 19, 2017
MBHB Partners Dr. Michael Borella, Dr. Kevin Noonan and Dr. Donald Zuhn Are Featured Presenters

Publications

March 21, 2017 (snippets Alert)
As was widely expected from the Justices’ positions at oral arguments, a nearly unanimous Supreme Court today struck down the patent laches doctrine in SCA Hygiene Prods. Aktiebolag, v. First Quality Baby Prods., LLC, 580 U.S. __ (March 21, 2017). In the opinion by Justice Alito, the Supreme Court applied the rationale of its own prior decision in Petrella v. Metro-Goldwyn-Mayer, Inc., 134 S. Ct. 1962 (2014), finding that the existence of a six-year statute of limitations in the Patent Act, 35 U.S.C. §286, precluded the application of laches. As such, “laches cannot be interposed as a defense against damages where the infringement occurred within the period prescribed by §286.”
Winter 2017 (snippets)
Owners of U.S. trademark registrations need to know about a few recent rule changes and be mindful of the changes and U.S. Patent and Trademark Office requirements whenever a declaration of use is due.
Winter 2017 (snippets)
In 2011, the Leahy-Smith America Invents Act (“AIA”) established new post-issuance procedures for challenging the validity of a granted patent before the Patent Trials and Appeal Board (“PTAB” or “Board”). Inter partes reviews (“IPRs”) and Covered Business Method patent reviews (“CBMs”) have been available since September 16, 2012, and their utilization since that time has exceeded expectations. A third mechanism, post-grant review (“PGR”), was also made available on that date, but because a PGR petition can only be filed for patents that were examined pursuant to the new First-Inventor-to-File scheme established by the AIA, it has not yet been significantly utilized. Here, we describe the IPR and PGR estoppel provisions of 35 U.S.C. §§ 315(e) and 325(e) and courts’ interpretations of those provisions thus far.
Winter 2017 (snippets)
Although the PTAB has instituted CBM trials for patents that do not facially qualify as business method patents, recent Federal Circuit decisions have required a more strict reading of the AIA statute in instituting CBM trials.
Winter 2017 (snippets)
Seeking to end years of little clarity on two key ethical issues for practitioners, the Patent Office has proposed two new rules of practice. The first rule would allow parties to invoke privilege in inter partes proceedings to prevent the disclosure of communications between clients and non-attorney patent agents. The second rule would change the duty of disclosure to comport with the standard set forth in the Therasense case. Based on the comments from the public, it appears likely that the Office will adopt the patent-agent privilege rule but go back for another round of changes to the duty of disclosure rule.
February 22, 2017 (snippets Alert)
MBHB snippets Alert - February 22, 2017

In an opinion by Justice Sotomayor, the Supreme Court today reversed the Federal Circuit's decision in Life Tech. Corp. v. Promega Corp. involving the proper scope of infringement under 35 U.S.C. § 271(f)(1). This provision provides infringement for exporting "all or a substantial portion of the components of a patented invention," and the Court's decision involved whether exporting only one component was enough for infringement liability.
Close
Generate a PDF of your page(s)
Clear
Close
Remove
Page has been queued
An error has occurred
Add
Added to queue
View
Confirm Delete All Message
No Items in Packet Message
To add a page, select Add. To view the package, select View.
false
http://www.mbhb.com/services/xpqServiceDetail.aspx?xpST=ServiceDetail&service=295&pdf=yes
a[href='javascript:packetBuilderSingleClick(document.title);']